62nd ASH Annual Meeting and Exposition: 902. Health Services Research—Malignant Conditions (Lymphoid Disease): Poster II

Oral and Poster Abstracts
Poster

Adult, ALL, antibodies, Biological, Leukemia, multiple myeloma, survivorship, CLL, Diseases, Lymphoma (any), Non-Biological, CAR-Ts, Hodgkin Lymphoma, Therapies, Adverse Events, chemotherapy, CNS Lymphoma, Non-Hodgkin Lymphoma, B-Cell Lymphoma, DLBCL, T-Cell Lymphoma, Technology and Procedures, immunotherapy, Plasma Cell Disorders, Lymphoid Malignancies, Study Population, Clinically relevant, Myeloid Malignancies, Quality Improvement , transplantation, TKI, stem cells

2498

A Clinical Practice Comparison of Overall Survival, Time-to-Next-Treatment, and Time-to-Treatment-Discontinuation Among CLL/SLL Patients Receiving First-Line Ibrutinib with and without a Del(17p) Mutation

Anthony Mato, MD¹^*, Boxiong Tang, MD, PhD², Soraya Azmi, MBBS, MPH²^*, Keri Yang, PhD, MPH, MS²^*, Jennifer C Stern, PhD³^*, Eric Hedrick, MD³, Jane Huang, MD⁴^* and Jeff P Sharman, MD⁵

¹Memorial Sloan Kettering Cancer Center, New York, NY
²BeiGene, Ltd., Emeryville, CA
³BeiGene, Ltd., Cambridge, MA
⁴BeiGene USA, Inc., San Mateo, CA
⁵Willamette Valley Cancer Institute, Eugene, OR

2499

Real-World Characteristics of Patients with Classical Hodgkin Lymphoma Receiving Frontline Brentuximab Vedotin with Chemotherapy: A Retrospective Analysis with Propensity Score Matching

Tycel J. Phillips, MD¹^*, Kristina Yu-Isenberg, PhD, MPH, RPh²^*, Nicholas Liu, PharmD²^*, Andy Surinach, MPH³^*, Carlos Flores, MPH³^*, Julie Lisano, PharmD²^*, Michelle A. Fanale, MD² and John M. Burke, MD⁴

¹Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan Medical School, Ann Arbor, MI
²Seattle Genetics, Bothell, WA
³Genesis Research, Hoboken, NJ
⁴US Oncology Hematology Research Program, Rocky Mountain Cancer Centers, Aurora, CO

2500

Cost and Healthcare Utilization in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Real-World Analysis of Medicare Beneficiaries Receiving Chimeric Antigen Receptor T-Cell Vs. Autologous and Allogeneic Hematopoietic Cell Transplants

Iman Mohammadi, PhD¹^*, Anna G Purdum, Pharmd MS²^*, Anny C Wong, PhD³^*, Amy Schroeder, BPharm¹^*, Karl M Kilgore, PhD⁴^* and Gunjan L. Shah, MD MS⁵

¹Avalere Health, An Inovalon Company, Washington, DC
²Kite Pharma, A Gilead Company, Santa Monica, CA
³Health Economics and Advanced Analytics, Avalere Health, An Inovalon Company, Washington, DC
⁴Health Economics and Advanced Analytics, Avalere Health, An Inovalon Company, Towson, MD
⁵Department of Medicine, Adult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, New York, NY

2501

Management of BTK Inhibitor Associated Adverse Events: Current Practice Trends Among Healthcare Providers and Concordance with Expert Recommendations

Kristen Rosenthal, PhD¹^*, Jeremy S Abramson, MD, MMSc², Farrukh T Awan, MD³, John P. Leonard, MD⁴, Julie M. Vose, MD, MBA⁵, Timothy A Quill, PhD⁶^* and Christopher Flowers, MD, MS⁷

¹CLINICAL CARE OPTIONS LLC, Reston, VA
²Massachusetts General Hospital Cancer Center, Boston, MA
³Division of Hematologic Malignancies and Stem Cell Transplantation, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX
⁴Weill Cornell Medical College, New York, NY
⁵Division of Oncology and Hematology, University of Nebraska Medical Center- Fred & Pamela Buffett Cancer Center, Omaha, NE
⁶Clinical Care Options, LLC, Reston, VA
⁷Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX

2502

Socioeconomic Disparities in Diagnostic Testing Among Patients with Diffuse Large B-Cell Lymphoma in the US

Fei Yang, MBBS, MMSc, PhD¹^*, Anup Abraham, MPH²^*, Ju Zhang, MSPH, PhD³^*, Yan Xiao, MD, PhD³^*, Richard D. Hammer, MD⁴^*, Donald C. Doll, MD^4,5 and Matthew S. Prime, BSc, MBBS, MRCS, PhD¹^*

¹Roche Diagnostics Information Solutions, Basel, Switzerland
²Genesis Research, Hoboken, NJ
³Roche Diagnostics Information Solutions, Belmont, CA
⁴University of Missouri, Columbia, MO
⁵Ellis Fischel Cancer Center, Columbia, MO

2503

Patient and Disease Factors Predict Risk of 1-Year Mortality Among Older Adults Who Receive Intensive Chemotherapy for Hodgkin Lymphoma (HL)

Anita J Kumar, MD, MS^1,2, Jason Nelson, MPH¹^*, Angie Mae Rodday, PhD¹, Andrew M. Evens, DO, MMSc³, Jonathan W. Friedberg, MD, MSSc⁴, Tanya M. Wildes, MD, MSc⁵ and Susan K Parsons, MD, MRP^1,6,7

¹Institute for Clinical Research & Health Policy Studies, Tufts Medical Center, Boston, MA
²Division of Hematology/Oncology, Tufts Medical Center, Winchester, MA
³Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
⁴Division of Hematology/Oncology, University of Rochester, Rochester, NY
⁵Washington University, Saint Louis, MO
⁶Division of Hematology/Oncology, Tufts Medical Center, Boston, MA
⁷Department of Medicine and Pediatrics, Tufts University School of Medicine, Boston, MA

2504

A Cross-Sectional Study Examining the Relationship between Patient Information Level and Patient Participation in Healthcare Decisions and Health Management

Natalie M Dren, BSc, MPH¹^* and Lorna E Warwick²^*

¹Research, Lymphoma Coalition, Mississauga, ON, Canada
²Management, Lymphoma Coalition, Mississauga, ON, Canada

2505

Racial Differences in Multiple Myeloma Survival and Treatment Using Pooled Clinical Trial and Real-World Electronic Medical Record Data

Emelly Rusli¹^*, Lihong Diao, MD MS²^*, Cynthia Liu^3,4^*, Mona A Kelkar, MBA^3,5^*, Lisa Ensign, PhD MS²^*, Mark Watson, MD PhD⁶^* and Aaron Galaznik, MD MBA¹

¹Acorn AI by Medidata, a Dassault Systèmes Company, Boston, MA
²Acorn AI by Medidata, a Dassault Systèmes Company, New York, NY
³Acorn AI Institute, Medidata, a Dassault Systèmes Company, New York, NY
⁴Columbia Mailman School of Public Health, New York, NY
⁵Harvard T.H. Chan School of Public Health, Boston, MA
⁶Guardian Research Network, Inc., Spartanburg, SC

2506

Economic Evaluation of Ibrutinib Versus Acalabrutinib Versus Zanubrutinib for Patients with Relapsed or Refractory Mantle Cell Lymphoma

Neda Alrawashdh, PharmD¹^*, Ali McBride, PharmD, MS^2,3, Marion Slack, Ph.D⁴^* and Ivo Abraham, PhD, RN⁵

¹Center for Health Outcomes and PharmacoEconomic Research, University of Arizona, TUCSON, AZ
²University of Arizona Cancer Center, Tucson, AZ
³Division of Hematology/Oncology, Department of Pharmacy, The University of Arizona Cancer Center, Tucson, AZ
⁴University of Arizona, TUCSON, AZ
⁵Center for Health Outcomes and PharmacoEconomic Research, University of Arizona - College of Pharmacy, Tucson, AZ

2507

Cost Avoidance from Automated Dose Rounding of Biological and Cytotoxic Anticancer Drugs in an Integrated Delivery Network

Amit Sanyal¹, Susan K Woelich, PharmD²^*, Matthew Mattila, PharmD³^*, Stephanie McCleary, PharmD⁴^*, James Thomas, PharmD⁵^* and Daniel Wellner, PharmD, BCPS⁶^*

¹SSM Health Cancer Care, Verona, WI
²SLU, St. Louis
³SSM Health, Fond Du Lac, WI
⁴SSM Health, St. Louis
⁵ssm health, St. Louis
⁶SSM Health Cancer Care, madison

2508

Comparison of Demographics, Treatment Patterns and Outcomes Among Primary Central Nervous System Lymphoma (PCNSL) Patients Treated at a Safety-Net Hospital Versus a Tertiary Academic Institution within the Same Healthcare System

Akshat M Patel, BA¹^*, Omer M Ali, MD¹, Radhika Kainthla, MD²^*, Syed M Rizvi, MD¹^*, Farrukh T Awan, MD¹, Neil B Desai, MD, MHS³^*, Robert Timmerman, MD³^*, Kiran A Kumar, MD, MBA³^* and Praveen Ramakrishnan Geethakumari, MD, MS¹

¹Division of Hematologic Malignancies and Stem Cell Transplantation, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX
²Parkland Health and Hospital System, Dallas, TX
³Department of Radiation Oncology, University of Texas Southwestern Medical Center, Dallas, TX

2509

Assessment of the Diagnostic Accuracy of Core Needle Biopsies in the Diagnosis of Lymphoma

Xiangyun Ye¹^*, Catherine Tucker, MD²^*, Christopher Gardner¹^*, Austin Redilla¹^*, Guldeep Uppal, MD³^* and Adam F. Binder, MD⁴

¹Sidney Kimmel Medical College, Philadelphia, PA
²Department of Pathology, Philadelphia, PA
³Pathology, Thomas Jefferson University, Philadelphia, PA
⁴Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation, Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA

2510

Cost-Effectiveness of Acalabrutinib Monotherapy Compared with Chlorambucil Plus Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Talha Munir, MBBS¹^*, Priyanka Gaitonde²^* and Catherine Waweru, PhD²^*

¹St James University Hospital, Leeds, United Kingdom
²AstraZeneca, Gaithersburg, MD

2511

Impact of Treatment Sequencing on Outcomes and Costs in Relapsed Follicular or Other Low Grade B-Cell Non-Hodgkin Lymphoma – Results of an Evidence-Based Budget Impact Model

Ali McBride, PharmD, MS¹ and Daniel O. Persky, MD²

¹Division of Hematology/Oncology, Department of Pharmacy, The University of Arizona Cancer Center, Tucson, AZ
²Division of Hematology/Oncology, University of Arizona, Tucson, AZ

2512

Comparing Effectiveness of Nitrous Oxide, Propofol, and Midazolam-Assisted Lumbar Punctures in Childhood Acute Lymphoblastic Leukemia

Lane Miller, MD, MSc¹^*, Mylynda Livingston, CNP²^*, Stuart S. Winter, MD³, Dave Watson, PhD⁴^* and Yoav H. Messinger, MD⁵

¹Cancer and Blood Disorders, Children's Minnesota, Minneapolis, MN
²Cancer & Blood Disorders, Children's Minnesota, Minneapolis, MN
³Children's Minnesota Research Institute, Children's Minnesota Research Institute and Cancer and Blood Disorders Program, Minneapolis, MN
⁴Research Institute, Children's Minnesota, Minneapolis, MN
⁵Children's Hospitals and Clinics, Minneapolis, MN

2513

ECOG Performance Status Shows a Stronger Association with Treatment Tolerability Than Some Multidimensional Scales in Elderly Patients Diagnosed with Hematological Malignancies

Fernando Ramos¹^*, Marta Castellanos, MD²^*, Natalia De las Heras, MD²^*, Fernando Escalante, MD²^*, Silvia Fernandez-Ferrero, MD PhD²^*, Maria Jesus Vidal, MD²^* and Maria Lavinia Villalobos, MD²^*

¹Department of Hematology, Hospital Universitario De LeóN and Instituto De Biomedicina (IBIOMED), Un, Leon, Spain
²Department of Hematology, Hospital Universitario de Leon, Leon, Spain

2514

Costs of Postinfusion Monitoring By Site of Care for Patients with Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Who Received Third-Line or Later Treatment with Lisocabtagene Maraleucel (liso-cel) in the Transcend NHL 001 and Outreach Trials

M. Lia Palomba, MD¹, Monika P. Jun, MPH²^*, Jacob Garcia, MD³^*, James Lymp, PhD³^*, November McGarvey⁴^*, Matthew Gitlin⁴^*, Corey Pelletier⁵^* and Andy Nguyen⁴^*

¹Memorial Sloan Kettering Cancer Center, New York, NY
²Bristol-Myers Squibb Company, Princeton, NJ
³Juno Therapeutics, a Bristol-Myers Squibb Company, Seattle, WA
⁴BluePath Solutions, Los Angeles, CA
⁵Bristol Myers Squibb, Princeton, NJ

2515

Demographic Differences in the Treatment and Mortality of Lymphoplasmacytic Lymphoma in Texas: Does Ethnicity Play Any Role?

Michael E Auster, DO¹^*, Snegha Ananth, MBBS^2,3, Lakene Raissa Djoufack Djoumessi, MD²^*, Qianqian Liu, PhD⁴^*, Joel E Michalek, PhD⁵^* and Adolfo Enrique Diaz Duque, MD, MSc⁶

¹University of Texas Health Science Center at San Antonio, San Antonio, TX
²University of Texas Health Science Center San Antonio, San Antonio, TX
³Hematology-Oncology, Mays Cancer Center UT Health San Antonio MD Anderson, San Antonio, TX
⁴Department of Epidemiology and Biostatistics, University of Texas Health at San Antonio, San Antonio, TX
⁵The University of Texas Health Science Center At San Antonio, San Antonio, TX
⁶Hematology-Oncology Division, Mays Cancer Center UT Health San Antonio MD Anderson, San Antonio, TX

2516

Comparison of Outcomes and Utilization of Therapy in Multiple Myeloma Patients in the USA and Alberta, Canada

Andrew J. Cowan, M.D.¹, Shasank R Chennupati, PharmD, MPH²^*, Yuan Xu, PhD³^*, Ang Li, MD, MS⁴, David A. Garcia, MD⁵, Edward Libby, MD⁶, Catherine Fedorenko, MMSci⁷^*, Scott D Ramsey, MD, PhD⁷^*, Veena Shankaran, MD^7,8^* and Winson Y Cheung, MD MPH⁹^*

¹Division of Medical Oncology, University of Washington, Seattle, WA
²Hutchinson Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Research Center, Seattle, WA
³Alberta Health Services, Calgary, AB, Canada
⁴Section of Hematology-Oncology, Baylor College of Medicine, Houston, TX
⁵Department of Medicine, Division of Hematology, University of Washington, Seattle, WA
⁶Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, WA
⁷Fred Hutchinson Cancer Research Center, Seattle, WA
⁸Medicine, University of Washington, Seattle, WA
⁹Department of Oncology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada

2517

Real-World Gaps in Chart Documentation and Patient-Centered Care Inform Team-Based Action Plans for Relapsed/Refractory DLBCL: Results from a Quality Improvement Study

F. B. B. Hagemeister, MD¹, Anne Jacobson, MS²^*, Jeffrey D Carter, PhD²^* and Tamar Sapir, PhD²^*

¹Department of Lymphoma/Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX
²PRIME Education, LLC, Ft Lauderdale, FL

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH